Compare PCT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | ADPT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | 174 | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | N/A | 2019 |
| Metric | PCT | ADPT |
|---|---|---|
| Price | $11.36 | $13.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.00 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $380.44 | $3.98 |
| Revenue Next Year | $203.33 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $4.93 | $8.97 |
| 52 Week High | $17.37 | $20.76 |
| Indicator | PCT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 50.69 |
| Support Level | $7.87 | $12.22 |
| Resistance Level | $15.13 | $15.27 |
| Average True Range (ATR) | 0.85 | 0.78 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 66.58 | 52.13 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.